AURA
Aura Biosciences, Inc.
$7.37
-0.13
(-1.73%)
Mkt Cap
762.33M
Volume
875,865
52W Range
4.73-9.535
Sector
Healthcare
Beta
0.40
EPS (TTM)
-1.78 USD
P/E Ratio
-3.10
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (106.19M) | (86.92M) | (76.41M) | (58.76M) | (35.25M) | (22.21M) | (24.20M) |
| EPS | -1.76 | -1.75 | -1.93 | -1.96 | -1.58 | -1.03 | -0.01 |
| Free Cash Flow | (85.19M) | (81.06M) | (64.56M) | (55.70M) | (34.53M) | (25.09M) | (22.89M) |
| FCF / Share | -1.41 | -1.63 | -1.63 | -1.86 | -1.18 | -0.86 | -0.01 |
| Operating CF | (84.74M) | (79.81M) | (63.85M) | (54.60M) | (32.41M) | (24.32M) | (20.67M) |
| Total Assets | 169.43M | 182.50M | 255.07M | 223.94M | 160.03M | 22.10M | 37.05M |
| Total Debt | 17.38M | 18.77M | 19.56M | 20.86M | 975,000 | 15,000 | 49,000 |
| Cash & Equiv | 59.52M | 31.69M | 41.06M | 121.58M | 149.06M | 17.39M | 32.47M |
| Book Value | 136.91M | 151.97M | 225.85M | 195.58M | 152.31M | 19.36M | 30.76M |
| Return on Equity | -0.78 | -0.57 | -0.34 | -0.30 | -0.23 | -1.15 | -0.79 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (45.64M) | (33.69M) | (25.56M) | (26.13M) | (27.02M) | (27.48M) | (25.83M) | (21.04M) | (20.34M) | (19.71M) | (22.13M) | (18.51M) |
| EPS | -0.48 | -0.50 | -0.40 | -0.40 | -0.47 | -0.55 | -0.52 | -0.42 | -0.41 | -0.40 | -0.50 | -0.48 |
| Free Cash Flow | (31.82M) | (30.00M) | (20.64M) | (20.19M) | (20.81M) | (23.54M) | (24.25M) | (15.61M) | (16.65M) | (24.54M) | (17.70M) | (15.49M) |
| FCF / Share | -0.34 | -0.44 | -0.34 | -0.31 | -0.36 | -0.47 | -0.49 | -0.31 | -0.34 | -0.50 | -0.40 | -0.41 |
| Operating CF | (31.80M) | (29.89M) | (20.47M) | (20.14M) | (20.77M) | (23.36M) | (23.95M) | (15.27M) | (16.13M) | (24.45M) | (17.39M) | (15.40M) |
| Total Assets | 348.13M | 137.68M | 169.43M | 190.02M | 204.40M | 155.40M | 182.50M | 205.34M | 218.28M | 235.03M | 255.07M | 179.77M |
| Total Debt | 16.59M | 16.99M | 17.38M | 17.75M | 18.11M | 18.44M | 18.77M | 19.08M | 19.03M | 19.32M | 19.56M | 20.19M |
| Cash & Equiv | 67.84M | 84.79M | 59.52M | 47.55M | 107.37M | 38.23M | 31.69M | 25.41M | 30.07M | 26.28M | 41.06M | 55.58M |
| Book Value | 315.27M | 107.25M | 136.91M | 156.67M | 174.63M | 127.97M | 151.97M | 174.67M | 191.45M | 208.78M | 225.85M | 151.72M |
| Return on Equity | -0.14 | -0.31 | -0.19 | -0.17 | -0.15 | -0.21 | -0.17 | -0.12 | -0.11 | -0.09 | -0.10 | -0.12 |
AURA News
Aura Biosciences to Participate in Upcoming Investor Conference
BlackRock Inc. Makes New Investment in Aura Biosciences, Inc. $AURA
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ADAR1 Capital Management LLC Acquires Shares of 130,152 Aura Biosciences, Inc. $AURA
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Auranova and Kenorland Announce Large Intrusion-Related Gold Discovery at the South Uchi Project, Ontario
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data